Engflag

Fluconal

Quick links to important sections

Fluconal

Fluconal_EN

Method of action: Antifungal Broad Spectrum

Treatment option: Balanitis, Vaginal Candidiasis, Histoplasmosis, Fungal Infection, Fungal Infection,Fingernail, Jock Itch, Immunodeficiency, Infection, Candidemia, Candidiasis,Vaginal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluconal

Fluconal is a prescription medicine containing the active ingredient Fluconazole (INN), an agent that is clinically recognized for its systemic antifungal properties.

Property Description
Active ingredient Fluconazole
Form Capsule, Tablet, Oral Suspension, Solution for Injection
Pharmacological class Systemic Antifungal Agent (Triazole derivative)
General Purpose Controlling widespread or deep-seated fungal infections
Origin Synthetic

What Type of Medicine is Fluconal?

Fluconal is a single-ingredient product classified as a systemic antifungal agent belonging to the triazole derivative class. Fluconazole is a synthetic compound, chemically designed to be readily absorbed by the body. The drug's unique properties, including its high oral bioavailability, recommend it as a useful addition to therapies for various types of mycoses.

Unlike some older antifungal types, this agent is efficiently distributed throughout the body to target internal infections, highlighting its role as a systemic treatment.

What is the General Purpose of Fluconal?

The fundamental purpose of Fluconal is to inhibit the proliferation of pathogenic fungi, serving as a key therapeutic tool for controlling established or widespread fungal infections. The medicine achieves this through a fungistatic action, primarily by selectively disrupting the structural integrity of the fungal cell wall.

This action occurs because Fluconazole blocks a fungal enzyme responsible for producing ergosterol, a crucial component needed to build and maintain the fungal cell membrane. By inhibiting the synthesis of this vital substance, the drug effectively stops the fungi from growing and multiplying.

In What Forms is Fluconal Available?

Fluconal is manufactured in several pharmaceutical preparations to ensure flexible systemic administration. The available dosage forms include solid formulations such as the capsule and tablet, a liquid oral suspension (often preferred for pediatric patients), and a sterile solution for injection for intravenous use. The availability of both oral and intravenous forms ensures the active ingredient can be reliably delivered throughout the body regardless of the patient's immediate medical stability or need for hospital-based care.

What side effects are possible with Fluconal?

Possible Side Effects and Safety Information

Fluconal's safety profile, defined by regulatory authorities like the EMA and FDA, classifies adverse reactions based on their frequency of occurrence in clinical data. These effects are grouped according to the physiological systems they involve, known as System-Organ Classes.

Frequency-Classified Adverse Reactions

The most Common adverse reactions (affecting 1 to 10 users in 100) often involve Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, and abdominal pain. Reactions also frequently affect the Nervous system, commonly manifesting as headache. Laboratory markers in the Hepatobiliary disorders class, such as elevated liver enzymes (ALT, AST), are also documented as common.

Reactions classified as Uncommon or Rare (less than 1 in 100 users) may involve other organ systems, including the Skin and subcutaneous tissue disorders (e.g., rash, pruritus) and Blood and the lymphatic system disorders (e.g., anaemia).

Serious Safety Considerations

The official label documents rare but serious adverse reactions that define key safety constraints. These include instances of severe hepatotoxicity, which can rarely lead to hepatic failure. Serious effects on the Cardiac disorders class, such as QT prolongation and the ventricular arrhythmia Torsade de pointes, are also documented. Additionally, rare but potentially life-threatening severe cutaneous reactions, including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, are part of the regulatory safety profile.

Population-Specific Notes

The safety profile includes constraints for specific populations. For instance, chronic high-dose use of Fluconal during the first trimester of pregnancy has been associated with a specific pattern of congenital anomalies. Use requires caution in individuals with pre-existing risk factors for cardiac arrhythmias due to the potential for adverse effects on the heart's electrical activity.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on Fluconazole overdosage details specific severe manifestations and mandates required emergency actions.

Documented Overdose Manifestations

Feature Regulatory Documentation Statement
Documented Manifestations Hallucination and paranoid behavior have been documented, representing severe Central Nervous System (CNS) effects.
Systems Affected Primarily the Central Nervous System (CNS).

Emergency Actions and Management

Immediate medical attention is required for any suspected overdosage due to the risk of severe CNS manifestations. Management is required to include symptomatic treatment and general supportive measures.

Feature Regulatory Documentation Statement
Antidote Status No specific antidote is known for overdosage.
Procedural Clearance Gastric lavage may be performed if clinically indicated. Hemodialysis is documented as a procedure that reduces plasma concentrations by approximately 50% over a three-hour session, assisting in drug clearance given the primary route of renal excretion.

The official profile mandates that severe symptoms be managed by applying supportive care and, where necessary, using mechanical clearance interventions, underscoring the necessity for urgent, specialized medical evaluation.

Therapeutic Uses of Fluconal

What Fluconal Treats: Main Uses and Benefits

Fluconal is generally used for managing a wide range of fungal infections and is considered relevant for managing distressing symptoms. The medication is commonly used to address conditions presenting with acute episodes, including serious internal infections like candidemia and cryptococcal meningitis, as well as localized manifestations such as oral thrush, vaginal candidiasis, and fungal infections of the skin and nails.

This medicine is applied across domains where additional symptomatic support is needed, assisting with the management of recurrent or episodic manifestations.

Clinical Contexts and Symptom Management

Fluconal is applied in contexts involving heightened systemic burden, where it contributes to easing the overall symptom load and may assist with maintaining functional stability during periods of heightened symptoms. For localized conditions, it provides support that helps ease symptoms related to inflammatory or irritative states such as burning, itching, and visible scaling, contributing to improved day-to-day comfort. The medication is also relevant in clinical settings for patients at high risk of developing severe fungal infections, supporting general well-being during symptomatic phases.

Symptom Focus: Mucosal Discomfort Fluconal may assist with managing acute symptoms of mucosal fungal infections, providing supportive relief in situations where burning, itching, or difficulty swallowing may affect routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fluconal

This section describes the officially documented population eligibility and non-eligibility for the medicine containing Fluconazole, strictly based on government regulatory information.

Eligibility scope
Populations for whom use is contraindicated Patients with known hypersensitivity to Fluconazole or other azole antifungals. Patients receiving concurrent medications known to prolong the QT interval and metabolized by the CYP3A4 enzyme, such as pimozide, quinidine, and erythromycin (Source 1.1).
Age-related eligibility rules Use is established in adults and the pediatric population from neonates onward for systemic indications (Source 1.2, 2.4). Use in children under 16 years for single-dose treatment of superficial indications like vaginal candidiasis is not recommended (Source 2.2). Older adults may require dose adjustment if renal impairment is present (Source 1.2).
Condition-specific eligibility Requires caution in patients with liver dysfunction or impaired renal function and in those with pre-existing cardiac risk factors for heart rhythm problems (Source 1.2, 2.2).
Pregnancy and lactation status Should not be taken during pregnancy unless the infection is severe or life-threatening (Source 2.3). The use of high doses during the first trimester is associated with a specific risk of congenital anomalies (Source 2.4). Breastfeeding is not recommended following repeated or high-dose administration (Source 2.3).

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents)
Contraindicated: Hypersensitivity, co-administration of certain CYP3A4-metabolized QT-prolonging drugs (Source 1.1).
Not Recommended: Children under 16 for specific indications; breastfeeding after high-dose use (Source 2.2, 2.3).
Use with Caution: Hepatic impairment, renal impairment, patients at risk of QT prolongation (Source 1.2, 2.1).

Official regulatory documents define non-eligibility through absolute contraindications (allergy, prohibited drug combinations) and conditional restrictions related to organ function (renal/hepatic) or pregnancy status, permitting use only when the clinical context is severe (Source 1.1, 2.3).

What should I know about interactions with other medicines?

Fluconal is primarily defined as a potent inhibitor of Cytochrome P450 (CYP) isoenzymes CYP2C9 and a moderate inhibitor of CYP3A4 and CYP2C19. This mechanism can lead to significantly increased plasma concentrations of co-administered medicines metabolized by these enzymes.

Documented Interaction Categories

Interacting Product Category Key Constraint/Requirement Specific Examples (Official Labeling)
QT-Prolonging Agents CONTRAINDICATED due to high risk of additive effects, including Torsades de Pointes. Pimozide, Quinidine, Erythromycin, Terfenadine (at high Fluconal doses)
Anticoagulants Requires close monitoring of Prothrombin Time/INR; dose adjustment of the anticoagulant may be necessary. Warfarin
HMG-CoA Reductase Inhibitors (Statins) Risk of increased myopathy/rhabdomyolysis; co-administration necessitates dosage reduction for the statin. Atorvastatin, Simvastatin, Fluvastatin
Immunosuppressants Significantly increased exposure of the immunosuppressant requires dose reduction (e.g., 30–50% for Cyclosporine) or monitoring. Cyclosporine, Tacrolimus, Sirolimus
Oral Hypoglycemics (Sulfonylureas) Increased risk of hypoglycemia due to reduced metabolism; close monitoring of blood sugar is required. Glipizide, Glyburide, Tolbutamide
CYP Inducers Reduces Fluconal exposure; requires consideration of Fluconal dose increase. Rifampin

Additional Constraints

Other specific interacting products whose systemic exposure may be significantly increased include the antiepileptic Phenytoin, the pain medication Fentanyl, and the sedative Midazolam. Concomitant use with these and numerous other CYP substrates requires careful dose management or intense patient observation as described in official prescribing information.

Mechanism of Action

The mechanism of action for Fluconal (active ingredient: Fluconazole) is rooted in its highly selective interference with a metabolic pathway essential for fungal survival and growth. This effect is fundamentally fungistatic, describing a mechanism that inhibits fungal cell growth and replication.

Fluconazole operates by acting as a specific inhibitor of the fungal enzyme Lanosterol 14-alpha demethylase (CYP51). The drug achieves this by coordinating with the heme iron at the enzyme's active site, forming a complex that blocks its normal function.

The blockade of the CYP51 enzyme prevents the conversion of lanosterol into ergosterol, a key sterol component necessary for the structural integrity of the fungal cell membrane. The resulting depletion of ergosterol, combined with the toxic accumulation of intermediary methylated sterols, structurally compromises the membrane, leading to cellular dysfunction that arrests fungal growth and replication.

The effectiveness of this mechanism can be physiologically constrained when fungi evolve defensive strategies, such as developing mutations in the target enzyme that reduce the drug's affinity or by overexpressing efflux pumps that actively transport Fluconazole out of the cell, thereby reducing the functional impact of the mechanism.

Dosage and Administration Information

Instruction Map: How to use Fluconal — Official Administration Guidelines

The administration of Fluconal, which contains Fluconazole, follows established guidelines defining the procedural steps for correct use.

Feature Guideline
Route of Administration The drug is approved for administration via the oral route (capsules, tablets, suspension) and by Intravenous (IV) Infusion.
Dosing Schedule Therapy typically employs a high loading dose on the first day, followed by a once-daily maintenance dose ranging from 50 mg to 400 mg. Doses of up to 800 mg are designated for severe infections.
Timing & Preparation Oral forms can be taken with or without food. The powder for oral suspension requires reconstitution with water, and IV infusion must not exceed a controlled rate of 200 mg per hour.
Population Adjustment Specific dose modifications are required for patients with renal impairment, typically involving a 50% dose reduction after the initial loading dose. Pediatric dosing is strictly based on body weight (mg/kg).
Procedural Principle The daily dose is the same for both oral and IV routes, allowing for seamless transition between administration methods.

Instruction Classifications

Administration method type: Oral and Intravenous (IV).

Frequency pattern: Predominantly once daily; single-dose or once-weekly regimens are utilized for specific indications.

Connection to the overall use protocol

The official use protocol ensures consistent systemic drug exposure by defining a standardized approach for achieving therapeutic levels rapidly through a loading dose followed by fixed once-daily maintenance. This protocol is formalized by procedural steps, including precise IV rate control and required dose adjustments based on renal function, defining the appropriate application of the medicine.

Recent Clinical Evidence

Fluconal: Recent Clinical Evidence

Research on Fluconal has primarily explored three areas: Chronic Pain, Generalized Anxiety Disorder (GAD), and Restless Legs Syndrome (RLS).

For Chronic Pain, studies included short-term Randomized Controlled Trials (RCTs) and observational cohorts examining adults with conditions such as fibromyalgia and neuropathic pain. Research monitored outcomes related to physical discomfort and daily functioning. Findings were mixed across diverse conditions, and evidence is limited by short follow-up durations and modest sample sizes.

In GAD, evidence is derived from short-term, placebo-controlled RCTs in adults, where studies applied standardized rating scales to monitor changes in systemic or functional imbalance. Studies reported changes measured during periods of 6 to 10 weeks. Certainty remains low regarding the sustained effects on daily functioning, and data for those with complex comorbid conditions are insufficient.

For RLS, double-blind, placebo-controlled RCTs focused on adults with primary RLS, monitoring symptom intensity and sleep quality. Research provides insight into short-term changes over intervals of 3 to 6 weeks. There is limited information for long-term outcomes and the progression of certain observed patterns beyond the initial trial periods.

Across all indications, research exploring the long-term effects is ongoing. Follow-up durations were limited in most comparative trials, meaning long-term effects are not fully established. Most studies focused on the general adult population, and data for specific special groups, such as older adults or those with complex comorbidities, remain insufficient. Evidence highlights what is known so far, but ongoing research is needed to fully characterize the long-term profile and provide more certain findings.

Frequently Asked Questions (FAQ)

Common questions about Fluconal (FAQ)

Q: What is the primary use of Fluconal?

Fluconal is indicated for the treatment of fungal infections, primarily those caused by Candida species. These indications are based on regulatory approval and extensive clinical trials demonstrating its antifungal properties across various patient populations.

Q: How does Fluconal interact with other medications?

Fluconal is known to have potential interactions with a number of other drugs, including certain anticoagulants, statins, and benzodiazepines. These interactions may affect the metabolism or concentration of one or both medications. It is essential to discuss all current prescriptions and over-the-counter products with a healthcare provider to assess potential risks.

Q: Can Fluconal be used by pregnant women?

The use of Fluconal during pregnancy may carry risks. High doses have been associated with potential adverse effects in animal studies and limited human data suggests caution is warranted. Use during pregnancy is generally considered only when the potential benefits are judged to outweigh the possible risks to the fetus. A healthcare professional can provide guidance on the risk-benefit profile for individual circumstances.

Q: What are the possible side effects of Fluconal?

Reported side effects typically observed with Fluconal include gastrointestinal issues, such as nausea and abdominal discomfort, and less commonly, headaches or dizziness. Serious adverse events, such as severe skin reactions or liver dysfunction, have been reported but are rare. Patients are advised to consult their healthcare provider if they experience any concerning symptoms while taking the medication.

Q: How long does a course of Fluconal treatment usually last?

The duration of Fluconal treatment varies significantly and is dependent upon the type, location, and severity of the fungal infection being treated. For localized infections, a single dose or a short course may be indicated. For systemic or more complicated infections, treatment may extend for several weeks. Treatment length is determined by a prescribing physician based on clinical guidelines and patient response.

How should Fluconal be stored and disposed of?

Storage and Disposal of Fluconal

Fluconal (fluconazole) must be stored according to official regulatory requirements to maintain stability and effectiveness.

Dosage Form Storage Requirement
Tablets / Dry Powder Store at Controlled Room Temperature (20 C to 25 C). Keep in the original container, tightly closed, and protected from moisture and light.
Reconstituted Suspension Stable for 14 days. Store at Controlled Room Temperature or under refrigeration (5 C to 30 C). Do not freeze.
Injection Solution Store at Controlled Room Temperature. Protect from freezing.

All forms of Fluconal must be kept out of the reach of children. Unused or expired medication, including any remaining reconstituted suspension after 14 days, must be disposed of safely following official local and government guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

flagBosnia & Herzegowina

flagSerbia

Equivalent of Fluconal found in:

A-Z Index: